Work

Immunotherapy in glioblastoma: emerging options in precision medicine

Year: 2016

Type: review

Abstract: Immunotherapy for glioblastoma (GBM) provides a unique opportunity for targeted therapies for each patient, addressing individual variability in genes, tumor biomarkers and clinical profile. As immunotherapy has the potential to specifically target tumor cells with minimal risk to normal tissue, several immunotherapeutic strategies are currently being evaluated in clinical trials in GBM. With the Precision Medicine Initiative being announced in the President's State of the Union Address in 2016, GBM immunotherapy provides a useful platform for changing the landscape in treating patients with difficult disease.

Source: CNS Oncology

DOI: 10.2217/cns-2016-0009

Authors: Tiffany R Hodges, Sherise D Ferguson, Amy B Heimberger

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute